Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 20 resultat
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168 (PERSEUS)
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months.
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months.
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months.
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months.
Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Test plan overview Project phase Phase II
Indication:
Complementary treatment of COVID 19
The purpose of the study:
Examine the efficacy and tolerance of a chlorine dioxide based preparation
Study design:
Quasi-experimental clinical case study
Number of patients expected:
20 patients.
Main inclusion
Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Masitinib is a selective, oral tyrosine kinase inhibitor with neuroprotective capability demonstrated via numerous preclinical studies. Two of masitinib's main cellular targets are the mast cell and microglia cell. It is well-established that mast cells play a prominent role in neuroinflammatory
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This is a phase I clinical trial to evaluate the safety, tolerability, and maximum tolerated dose of DMF in patients with chronic lymphocytic leukemia. Patients with relapsed/refractory CLL not amenable to available therapies are eligible. This patient population is in need of novel therapies,
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in tuberous sclerosis complex 1 (TSC1) or TSC2 tumor suppressor genes. TSC is characterized by tumors in a wide range of tissues, seizures, mental retardation, autism, and organ failure. Lymphangioleiomyomatosis
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Masitinib is novel tyrosine kinase inhibitor that targets microglia and mast cells through inhibiting a limited number of kinases. Masitinib blocks microglia proliferation and activation, and mast cell-mediated degranulation, the release of cytotoxic substances that might further damage the motor
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Chronic Graft versus Host Disease (cGvHD) has been identified as the leading cause of late non-relapse mortality in Hemopoietic Stem Cell Transplant (HSCT) survivors. Up to now a standard satisfactory treatment for these patients does not exist. cGVHD is an immune-mediated disease, resulting from a
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Systemic sclerosis (SSc, scleroderma) is a multisystem autoimmune rheumatic disease that causes inflammation, vascular damage and fibrosis. Besides involvement of skin, fibrosis also affects many internal organ involving blood vessel, lungs, heart, kidney etc. Although advances in understanding in
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes. The objective of this study
The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The immune and clinical impacts of vitamin D in patients with chronic musculo-skeletal pain
Background Vitamin D is a group of fat-soluble secosteroids, the two major physiologically relevant forms are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D without a subscript refers
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
